The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Optruma raloxifene | Eli Lilly Nederland B.V. | Osteoporosis, Postmenopausal | 🇪🇺 EU 1998-08-05 | Order → |
| Xenical orlistat | CHEPLAPHARM Arzneimittel GmbH | Obesity | 🇪🇺 EU 1998-07-29 | Order → |
| EchoGen dodecafluoropentane | Sonus Pharmaceuticals Ltd. | Echocardiography | 🇪🇺 EU 1998-07-17 | Order → |
| Plavix clopidogrel | Sanofi Winthrop Industrie | Stroke; Peripheral Vascular Diseases; Atrial Fibrillation; Myocardial Infarction; Acute Coronary Syndrome | 🇪🇺 EU 1998-07-15 | Order → |
| Iscover clopidogrel | Sanofi Winthrop Industrie | Stroke; Peripheral Vascular Diseases; Atrial Fibrillation; Myocardial Infarction; Acute Coronary Syndrome | 🇪🇺 EU 1998-07-14 | Order → |
| Turvel trovafloxacin | Pfizer Limited | Bacterial Infections | 🇪🇺 EU 1998-07-08 | Order → |
| Trovan trovafloxacin | Pfizer Limited | Bacterial Infections | 🇪🇺 EU 1998-07-03 | Order → |
| Trovan IV trovafloxacin | Pfizer Limited | Bacterial Infections | 🇪🇺 EU 1998-07-03 | Order → |
| Turvel IV trovafloxacin | Pfizer Limited | Bacterial Infections | 🇪🇺 EU 1998-07-03 | Order → |
| Pylori-Chek 13C-urea | Alimenterics B.V. | Breath Tests; Helicobacter Infections | 🇪🇺 EU 1998-06-15 | Order → |
| MabThera rituximab | Roche Registration GmbH | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell | 🇪🇺 EU 1998-06-02 | Order → |
| Optison perflutren | GE Healthcare AS | Echocardiography | 🇪🇺 EU 1998-05-17 | Order → |
| Exelon rivastigmine | Novartis Europharm Limited | Dementia; Alzheimer Disease; Parkinson Disease | 🇪🇺 EU 1998-05-11 | Order → |
| Pylobactell 13C-urea | Richen Europe S.R.L | Breath Tests; Helicobacter Infections | 🇪🇺 EU 1998-05-07 | Order → |
| Rebif interferon beta-1a | Merck Europe B.V. | Multiple Sclerosis | 🇪🇺 EU 1998-05-03 | Order → |
| Combivir lamivudine;zidovudine | ViiV Healthcare BV | HIV Infections | 🇪🇺 EU 1998-03-18 | Order → |
| Mirapexin pramipexole | Boehringer Ingelheim International GmbH | Restless Legs Syndrome; Parkinson Disease | 🇪🇺 EU 1998-02-23 | Order → |
| Primavax diphtheria, tetanus and hepatitis B (rDNA) vaccine (adsorbed) | Pasteur Mà¨rieux MSD | Hepatitis B; Tetanus; Immunization; Diphtheria | 🇪🇺 EU 1998-02-05 | Order → |
| Quadramet samarium [153Sm] lexidronam pentasodium | CIS bio international | Pain; Cancer | 🇪🇺 EU 1998-02-04 | Order → |
| Viramune nevirapine | Boehringer Ingelheim International GmbH | HIV Infections | 🇪🇺 EU 1998-02-04 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.